Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
Sign Up to like & getrecommendations! Published in 2022 at "Gut"
DOI: 10.1136/gutjnl-2022-327059
Abstract: Objective The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this immunotherapy with a HBV vaccine to achieve… read more here.
Keywords: immune tolerance; pdl1; hbv; pdl1 ifn ... See more keywords